Human papillomavirus vaccine trials and tribulations : Vaccine efficacy - 15/10/15
Abstract |
As of December 2014, there were 3 approved vaccines for human papillomavirus (HPV): bivalent Cervarix (GlaxoSmithKline, New York, NY), quadrivalent Gardasil (Merck and Co, Kenilworth, NJ), and 9-valent Gardasil-9 (Merck and Co). The average cost per dose is $120, with a recommended 3-dose course. The quadrivalent vaccine is the most widely administered worldwide. As with the bivalent and 9-valent vaccines, the vaccine is considered safe, although concerns have been raised. In addition to immunization against the targeted HPV types, there is evidence that there is cross protection against other types of HPV. This continuing medical education review evaluates the differences in vaccines that are currently on the market; part II focuses on the cost-effectiveness of vaccination, the HPV vaccination programs currently instituted around the globe, efficacy, and safety.
Le texte complet de cet article est disponible en PDF.Key words : anal cancer, Cervarix, cervical cancer, condylomas, Gardasil, human papillomavirus, vaccine
Abbreviations used : ACA, ACIP, AIN, CDC, CHMP, CIN, FDA, HPV, ICER, MSM, MSW, OPSCC, QALY, VLP
Plan
Funding sources: None. |
|
Conflicts of interest: None declared. |
|
Date of release: November 2015 |
|
Expiration date: November 2018 |
Vol 73 - N° 5
P. 759-767 - novembre 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?